Related references
Note: Only part of the references are listed.Clinical validity of circulating tumor cell (CTC) enumeration in 841 subjects with metastatic breast cancer (MBC).
M. C. Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study
V. Georgoulias et al.
ANNALS OF ONCOLOGY (2012)
Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients
Brigitte Rack et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2012)
Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study
Francois-Clement Bidard et al.
BREAST CANCER RESEARCH (2012)
Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients
Antonio Giordano et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients
Marie-Christine Etienne-Grimaldi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Multi-parameter molecular characterization of circulating tumor cells (CTC): Development of a CTC-endocrine therapy index (CTC-ETI)
Costanza Paoletti et al.
CANCER RESEARCH (2011)
Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer
F. -C. Bidard et al.
ANNALS OF ONCOLOGY (2010)
Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy
F. -C. Bidard et al.
ANNALS OF ONCOLOGY (2010)
HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial
Tanja Fehm et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Prognostic Relevance of Circulating Tumor Cells in the Peripheral Blood of Primary Breast Cancer Patients
B. Rack et al.
CANCER RESEARCH (2010)
Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial
Sabine Riethdorf et al.
CLINICAL CANCER RESEARCH (2010)
Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review
Shaheenah Dawood et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer
Seigo Nakamura et al.
BREAST CANCER (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Variation of circulating tumor cell levels during treatment of metastatic breast cancer:: prognostic and therapeutic implications
F. Nole et al.
ANNALS OF ONCOLOGY (2008)
Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial
Jean-Yves Pierga et al.
CLINICAL CANCER RESEARCH (2008)
HER2 status and benefit from adjuvant trastuzumab in breast cancer
Soonmyung Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
Tanja Fehm et al.
BREAST CANCER RESEARCH (2007)
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies
NL Spector et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
M Cristofanilli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
HER-2 gene amplification can be acquired as breast cancer progresses
SD Meng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: Evaluation of their prognostic significance
A Stathopoulou et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)